Carisbamate

Phase 3Small molecule

SSK Life Science, Inc.

Carisbamate is one of 180 small molecule programs targeting Lennox-Gastaut syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

179

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lennox-Gastaut SyndromeActive, not recruiting

Alcohol DependenceActive, not recruiting

SeizureActive, not recruiting

Postherpetic NeuralgiaActive, not recruiting

EpilepsyActive, not recruiting

Essential TremorActive, not recruiting

Lennox-Gastaut SyndromePhase 1

Active, not recruiting

Alcohol DependencePhase 1/Phase 2

Active, not recruiting

SeizurePhase 3

Active, not recruiting

Postherpetic NeuralgiaPhase 2

Active, not recruiting

EpilepsyPhase 3

Active, not recruiting

Essential TremorPhase 2

Active, not recruiting

Competition

Competitive Landscape

221 competitors in Epilepsy

#DrugCompanyPhaseTrials

Briviact

UCB

Phase 3

14 2

Epidiolex

Jazz Pharmaceuticals

Phase 3

9 3

Dayvigo

Eisai

Phase 3

1 4

Fintepla

IImmedica Pharma AB

Phase 3

4 5

Actemra

Roche

Phase 3

—6

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

3 7

Narcan

SScienture

Phase 3

1 8

GWP42003-P

Jazz Pharmaceuticals

Phase 3

1 9

Immunoglobulin

Sanofi

Phase 3

1 10

Akineton

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Seizure

NCT05219617

Clinical

Trials by Indication[1]

Seizure4 trials

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Recruiting·SSK Life Science, Inc.·Phase 3·NCT05219617·252 enrolled

An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures

Completed·SSK Life Science, Inc.·Phase 3·NCT00744731·403 enrolled

An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.

Completed·SSK Life Science, Inc.·Phase 3·NCT00991757·991 enrolled

Show 1 more trial

A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.

Completed·SSK Life Science, Inc.·Phase 3·NCT00740623·547 enrolled

Lennox-Gastaut syndrome2 trials

Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome

Completed·SSK Life Science, Inc.·Phase 1·NCT04062981·15 enrolled

Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome

Completed·SSK Life Science, Inc.·Phase 1·NCT03731715·18 enrolled

Alcohol Dependence1 trial

Carisbamate as a Potential Treatment for Alcohol Dependence

Completed·—·Phase 1/2·NCT02435381·11 enrolled

CAR1 trial

Bioavailability and Food Effect Study of 3 Types of Carisbamate

Completed·SSK Life Science, Inc.·Phase 1·NCT04520360·33 enrolled

Epilepsy1 trial

Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.

Terminated·SSK Life Science, Inc.·Phase 3·NCT00563459·89 enrolled

2 more indications

Essential Tremor1 trial

A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor

Completed·SSK Life Science, Inc.·Phase 2·NCT00524056·62 enrolled

Postherpetic Neuralgia1 trial

An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN).

Completed·SSK Life Science, Inc.·Phase 2·NCT00492323·91 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Carisbamate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carisbamate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carisbamate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SK Life Science, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSK Life Science, Inc.

Carisbamate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Seizure4 trials

Lennox-Gastaut syndrome2 trials

Alcohol Dependence1 trial

CAR1 trial

Epilepsy1 trial

Essential Tremor1 trial

Postherpetic Neuralgia1 trial

References

Drug Info

Quick Facts

Related News